Key result
Direct oral anticoagulants provide an effective alternative for managing pediatric thrombosis, though real-world evidence is lacking for children who do not meet clinical trial inclusion criteria.
Why the study?
There is a paucity of real-world evidence to guide the use of direct oral anticoagulants in children who would not have met clinical trial inclusion criteria.
Do direct oral anticoagulants improve the management and prevention of thrombosis in pediatric patients?
Do direct oral anticoagulants improve the management and prevention of thrombosis in pediatric patients?
DOACs offer a promising, monitoring-free alternative for pediatric anticoagulation, but their use requires careful patient selection due to limited data in infants, severe renal/hepatic impairment, and antiphospholipid syndrome.
Direct oral anticoagulants (DOACs) provide an attractive alternative for the management and prevention of thrombosis in pediatric patients. With multiple ongoing and published pediatric trials and recent regulatory approval of dabigatran and rivaroxaban, the landscape of pediatric anticoagulation is rapidly changing. However, as pediatricians gain experience with these drugs, it is important to be mindful of pediatric-specific considerations that may limit the use of DOACs in certain children and adolescents. While there is increasing adult data and experience, there is a paucity of real-world evidence to guide the use of these drugs in children who would not have met clinical trial inclusion criteria. In this mini review, we summarize pediatric specific data, areas for future research, and practical considerations for the use of DOACs in children and adolescents.
No takes yet. Share an insight, caveat, or question.
Whitworth et al. (2022) conducted a review in Venous thromboembolism (VTE) and thrombosis. Direct oral anticoagulants (DOACs) vs. Standard of care (UFH, LMWH, VKA) was evaluated. Direct oral anticoagulants provide an effective alternative for managing pediatric thrombosis, though real-world evidence is lacking for children who do not meet clinical trial inclusion criteria.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: